First-in-Human Study of ABS-169 in Healthy Volunteers (PATH-169)

November 11, 2026 updated by: Aerys Biosciences

A Phase I, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-169 in Healthy Volunteers

This is the first study of ABS-169 in people. ABS-169 is an oral investigational medicine that blocks MD2-TLR4 signalling, a pathway involved in inflammation and scarring (fibrosis) of organs such as the heart. The study will test single doses of ABS-169 or placebo in healthy adult volunteers to find out how safe and well tolerated it is, how much of the medicine gets into the blood and how quickly it is removed, and whether taking it with a high-fat meal changes how it is absorbed. Up to 40 healthy adults aged 18 to 55 will take part at one study centre in Melbourne, Australia.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

ABS-169-001 is a single-site, randomised, double-blind, placebo-controlled, first-in-human study with 4 sequential single ascending dose (SAD) cohorts (25, 75, 150 and 200 mg, fasted) and one stand-alone food-effect cohort (25 mg, fed). Each cohort enrols 8 new participants randomised 6:2 to ABS-169 or matching placebo.

Each cohort starts with 2 sentinel participants (1 ABS-169, 1 placebo); the remaining 6 are dosed only after review of at least Day 2 safety data from the sentinels. Participants are screened from Day -28, admitted on Day -1, receive a single oral dose on Day 1, remain confined until Day 3, and return for an end-of-study visit on Day 7 (±1 day). Fasted cohorts fast for at least 10 hours before and 4 hours after dosing. In the food-effect cohort, participants eat a standard high-fat breakfast starting 30 minutes before dosing and finish it within 30 minutes.

Blood samples for ABS-169 and its metabolite dihydroartemisinin (DHA) are taken before dosing and at 5, 15 and 30 minutes and 1, 1.5, 2, 4, 8, 12 and 24 hours after dosing.

A Safety Review Committee reviews blinded safety data through Day 7 and blinded PK data to 24 hours before each dose escalation. Escalation requires evaluable data from at least 7 of 8 participants, including both sentinels. The projected mean exposure at the next dose must also stay within the exposure limit (Cmax 2,460 ng/mL; AUC 4,470 h·ng/mL), which is the exposure at the no-observed-adverse-effect level in the 28-day rat toxicology study. Intermediate or lower dose levels may be used, but the maximum dose will not exceed 200 mg without a protocol amendment.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Nucleus Network recruitment team Recruiting Site
  • Phone Number: 1800 243 733

Study Locations

    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Nucleus Network Pty Ltd
        • Contact:
          • Ofer Gonen
        • Principal Investigator:
          • Ofer Gonen, MBBS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Written informed consent given before any study-related activities, with understanding of the nature, purpose, risks and adverse effects of the study.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 at Screening.
  4. Medically healthy in the opinion of the PI or delegate, without clinically significant abnormalities, including: normal physical examination; systolic BP 90-140 mmHg and diastolic BP 40-90 mmHg; pulse rate 40-100 bpm; tympanic temperature 35.5-37.5°C; ECG without clinically significant abnormalities including QTcF <450 msec; respiration rate 10-22 breaths/min; SpO2 ≥95%; no clinically significant findings in clinical chemistry, haematology, coagulation and urinalysis.
  5. Female volunteers must agree not to donate ova until at least 35 days after dosing and must either be of non-childbearing potential (surgically sterilised at least 6 weeks before Screening, or postmenopausal with confirmatory FSH), or, if of childbearing potential, have negative pregnancy tests at Screening and Day -1, agree not to attempt pregnancy, and use adequate contraception (male partner condom plus a highly effective non-hormonal method) from one month before Screening until at least 35 days after dosing, unless exclusively in a same-sex relationship or abstinent as a committed lifestyle.
  6. Male volunteers must agree not to donate sperm until at least 95 days after dosing. With a female partner who could become pregnant, they must use a condom plus a highly effective method of contraception until at least 95 days after dosing. With a partner of non-childbearing potential or a same-sex partner, they must use a condom until at least 5 days after dosing.
  7. Suitable venous access for blood sampling.
  8. Willing and able to comply with all study assessments, schedule and restrictions.

Exclusion Criteria:

  1. Known hypersensitivity to the study drug or any of its ingredients.
  2. History of anaphylaxis or other significant allergy that would interfere with participation.
  3. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric or neurological disease, including any clinically relevant acute illness within the past 3 months.
  4. Major surgery or hospitalisation within 3 months before Screening, minor surgery under local anaesthetic within 1 month before Screening, or surgery planned during the study.
  5. Malignant disease in the last 10 years (except surgically resected skin squamous or basal cell carcinoma).
  6. Clinically relevant immunosuppression, including immunodeficiency conditions.
  7. Risk factors for torsade de pointes (including family history of long QT syndrome or sudden cardiac death) or a known arrhythmia.
  8. Gastrointestinal, liver (including Gilbert's syndrome), kidney or other conditions known to interfere with drug absorption, distribution, metabolism or excretion.
  9. History of known or unexplained bleeding disorders, or positive faecal occult blood test at Screening.
  10. GGT, bilirubin, ALP, AST or ALT >1.5× ULN. ALP/ALT/AST elevations may be accepted at PI discretion if they are normal variants without clinical signs.
  11. Estimated creatinine clearance <60 mL/min (Cockcroft-Gault) or serum creatinine >1.5× ULN.
  12. QTcF >450 msec (males) or >470 msec (females) confirmed on repeat; history of hypokalaemia or family history of long QT syndrome; or use of QT/QTc-prolonging medicines.
  13. Within 48 hours before dosing: caffeine or other xanthine-containing food or drink; foods that induce or inhibit liver enzymes (e.g., grapefruit, pomegranate, mango, dragon fruit); alcohol; or other factors affecting drug ADME, such as strenuous exercise.
  14. History of, or positive Screening test for, HIV, hepatitis B surface antigen or hepatitis C antibodies.
  15. Positive drugs-of-abuse or alcohol breath test at Screening or Day -1 (positive cotinine at Screening is not exclusionary).
  16. Regular consumption of more than 10 standard drinks per week or more than 4 standard drinks on any one day.
  17. Smoking more than 5 cigarettes (or equivalent nicotine products) per week, or unwilling to abstain from 72 hours before Day -1 and throughout confinement.
  18. Females who are breastfeeding or plan to breastfeed from Screening until 3 months after dosing.
  19. Unable to swallow oral medication.
  20. Use of any prescription or over-the-counter medication, including herbal products, vitamins and hormone supplements, within 7 days or 5 half-lives (whichever is longer) before dosing. Exceptions: contraceptives, paracetamol up to 2 g/day and ibuprofen up to 1.2 g/day, each for no more than 3 consecutive days. Drugs with known risk of TdP are prohibited.
  21. Current infection requiring systemic antibiotic, antifungal, antiparasitic or antiviral medication within 10 days before dosing.
  22. Any vaccination within 30 days before Screening.
  23. Blood or plasma donation, or blood loss >500 mL, within 30 days before dosing, or blood transfusion within 1 year.
  24. Participation in a study of an investigational drug or device within 30 days or 5 half-lives (whichever is longer) before Screening.
  25. Any other condition or prior therapy that, in the PI's opinion, makes the volunteer unsuitable, including likely non-compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort A1: ABS-169 25 mg (fasted)

Single oral dose of ABS-169 25 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Experimental: Cohort A2: ABS-169 75 mg (fasted)

Single oral dose of ABS-169 75 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Experimental: Cohort A2 (FE): ABS-169 25 mg (fed)

Single oral dose of ABS-169 25 mg on Day 1 after a standard high-fat breakfast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Experimental: Cohort A3: ABS-169 150 mg (fasted)

Single oral dose of ABS-169 150 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Experimental: Cohort A4: ABS-169 200 mg (fasted)

Single oral dose of ABS-169 200 mg on Day 1 after an overnight fast (n=6)

Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water

Placebo Comparator: Placebo (pooled across cohorts)

Single oral dose of matching placebo on Day 1, fasted or fed according to cohort (n=2 per cohort, up to 10)

Matching oral capsule containing microcrystalline cellulose, single dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Day 1 (dosing) through Day 7 (plus or minus 1 day)

TEAEs, including serious AEs, by severity and relationship to study drug (MedDRA). AEs are recorded from signing of consent; TEAEs are those starting or worsening after dosing.

Day 1 (dosing) through Day 7 (plus or minus 1 day)
Number of participants with clinically significant abnormalities in vital signs, 12-lead ECGs, clinical laboratory tests or physical examination
Time Frame: Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Vital signs: blood pressure, pulse rate, respiratory rate, temperature, SpO2. ECG: including QTcF. Laboratory: haematology, chemistry, coagulation, urinalysis. Clinical significance is judged by the investigator.

Baseline (Screening and Day -1) through Day 7 (plus or minus 1 day)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Observed Plasma Concentration (Cmax) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

Cmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

Tmax of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

AUClast of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

AUCinf of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Terminal Elimination Half-life (t1/2) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

t1/2 of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Oral Clearance (CL/F) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

CL/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Apparent Volume of Distribution During the Terminal Phase (Vz/F) of ABS-169
Time Frame: Pre-dose through 24 hours post-dose

Vz/F of ABS-169 after a single oral dose, by non-compartmental analysis, for each cohort (25, 75, 150 and 200 mg fasted; 25 mg fed).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 Cmax
Time Frame: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed Cmax versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Dose Proportionality of ABS-169 AUCinf
Time Frame: Pre-dose through 24 hours post-dose

Slope estimate with 90% confidence interval from a power model of log-transformed AUCinf versus log-transformed dose across 25 to 200 mg (fasted cohorts).

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 Cmax
Time Frame: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for Cmax, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose
Effect of Food on ABS-169 AUCinf
Time Frame: Pre-dose through 24 hours post-dose

Geometric mean ratio (fed/fasted) with 90% confidence interval for AUCinf, comparing 25 mg fed (Cohort A2-FE) with 25 mg fasted (Cohort A1), from a general linear model on log-transformed data.

Pre-dose through 24 hours post-dose

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of ABS-169 Metabolites in Plasma
Time Frame: Pre-dose through 24 hours post-dose

Qualitative identification of ABS-169 and its metabolite if significant.

Pre-dose through 24 hours post-dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ofer Gonen, MBBS, Nucleus Network Pty Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

October 22, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ABS-169-001
  • 2026-09-1741 (Other Identifier: Bellberry Limited Human Research Ethics Committee (Bellberry Application No.))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

"There is no plan to make individual participant data available. Summary results will be posted on ClinicalTrials.gov."

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe